A PHASE 1 TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PD of AX-0810 IN HEALTHY PARTICIPANTS
Latest Information Update: 26 May 2026
At a glance
- Drugs AX 0810 (Primary)
- Indications Liver disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms PQ-0810-001
- Sponsors ProQR Therapeutics
Most Recent Events
- 12 May 2026 According to a ProQR Therapeutics media release, the company remains on track to report target engagement data from healthy volunteers in the second quarter of 2026.
- 08 Jan 2026 Results presented the Media Release ProQR Therapeutics media release.
- 08 Jan 2026 Status changed from not yet recruiting to recruiting.